Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.

Abstract: This invention relates to isolated polypeptides that are long acting analogs of human PYY. The disclosed PYY analog polypeptides have beneficial physicochemical properties relative to endogenous PYY and known synthetic PYY analog polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed PYY analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed PYY analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).

Abstract: This invention relates to isolated polypeptides that are long acting analogs of human GLP-1. The disclosed GLP-1 receptor agonist polypeptides have beneficial physicochemical properties relative to endogenous GLP-1 and known synthetic GLP-1 receptor agonist polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed GLP-1 receptor agonist polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed GLP-1 receptor agonist polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).

Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.

Abstract: An emergency evacuation tool that is configured to be mounted within an operator cab of heavy equipment wherein the tool of the present invention is operable to facilitate evacuation of the cab by cutting through the safety cage surroundably present thereto. The present invention includes a housing having a motor and a power supply disposed in the interior volume thereof. A blade is present on one end of the housing wherein the blade is adjustable and axially aligned with the housing. The blade is surroundably mounted by a blade guard housing. The lower edge of the blade guard housing provides stabilization during use. A spark receiving member is secured to the blade guard housing. The emergency evacuation tool is releasably secured to a mounting case that is electrically coupled to the heavy equipment. The housing includes at least one handle that is rotatable about the housing.

Abstract: This invention relates to isolated polypeptides that are long acting analogs of human PYY. The disclosed PYY analog polypeptides have beneficial physicochemical properties relative to endogenous PYY and known synthetic PYY analog polypeptides, such as longer (i.e., “long-acting”) elimination half-lives (t1/2), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed PYY analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed PYY analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).

Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.

Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.

Abstract: This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1/2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.

Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.

Abstract: This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.

Abstract: A support frame for use in a wind turbine including a tower and a rotor that is rotatably coupled to a rotor shaft. The support frame includes an upper portion including an inner surface, an outer surface, and at least one bearing housing that is sized to receive the rotor shaft therethrough. A lower portion is integrally formed with the upper portion and extends from the upper portion. The lower portion includes a support flange that is configured to be coupled to the tower to support the rotor shaft and the rotor from the tower.

Abstract: Disclosed are compounds of Formula (I) wherein G, R2, A, D and E are as described in the specification, or pharmaceutically-acceptable salts, or in vivo-hydrolysable precursors thereof. Also disclosed herein is at least one method of making, at least one pharmaceutical composition containing, and at least one method for using at least one compound in accordance with Formula I.

Abstract: Compounds of Formula I wherein R1, D, R2, A and R3 are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Abstract: A method for assembling a power system is provided. The method includes coupling a first turbine and second turbine together with a coupling that extends between a first rotor of a first turbine and a second rotor of the second turbine, and such that the first turbine has fluid flow along a first flow path, and the second turbine has fluid flow along a second flow path. The method further includes fixedly coupling an outer wall to the first turbine that directs fluid flow from the first flow path towards the second flow path.

Abstract: A method for assembling a power system is provided. The method includes coupling a first turbine and second turbine together with a coupling that extends between a first rotor of a first turbine and a second rotor of the second turbine, and such that the first turbine has fluid flow along a first flow path, and the second turbine has fluid flow along a second flow path. The method further includes fixedly coupling an outer wall to the first turbine that directs fluid flow from the first flow path towards the second flow path.

Abstract: A remote sensor for detecting a nuclear source, comprises: a Field-of-View (FOV) structure having an aperture therethrough of area A and a Field-of-View (FOV) angle, the FOV angle centered on a source, and subtending a solid angle &OHgr; to the nuclear source; a plurality of optical filters for filtering photons outside a selected Ultraviolet (UV) band and for transmitting in-band photons according to a selected Transfer Function defining an out-of-band rejection ratio and an in-band transmittance ratio for the selected UV band, the Transfer Function supporting a sensor sensitivity S at the selected UV band for the Field-of-View (FOV) structure to support a Signal-to-Noise ratio of greater than one (1) to detect a nuclear source of nuclear material having a brightness of at least about IR, the selected UV band being selected such that naturally occurring in-band photons are at a brightness of about less than 104 R during daylight and are not naturally occurring at night up to about 20 km Earth altitude, and t

Abstract: A process and apparatus for producing a polymeric foam, wherein foam components are brought together under pressure and are passed through a permeable discharge head where the pressure is reduced. The permeable discharge head comprises a diffuser element having a structure such as to require division, divergence and convergence of flow paths in three dimensions within its axial thickness, considered in the direction of flow therethrough. The diffuser element comprises plural individual woven wire meshes sintered together to form a composite element. The invention also provides the diffuser element.

Abstract: An apparatus and process for producing polymeric foam, wherein reactive foam components and a low-boiling point frothing agent are brought together, sufficient pressure is applied to maintain the frothing agent in a liquid state and the mixture is passed through a permeable discharge head through which the mixture is discharged and wherein the pressure is reduced and froth is formed. The discharge head comprises one or more diffuser elements (80) having a structure such as to require division, divergence and convergence of flow paths in three dimensions within the axial thickness of the diffuser element, considered in the direction of flow therethrough. The diffuser element (80) is made of bonded, or sintered or sintered composite material, such as sintered wire.

Abstract: A rigid type swimming pool or other rigid type structure formed in the ground in which the excavated sides and bottom provides the form for the rigid shell, is subject to increased pressures from the soil, where the surrounding soil is of the expansive clay type. Clay, being of fine soil particles, expands when there is the presence of water, and contracts when there is loss of water. In such a case, flexible, porous expansion material can be placed between the soil and shell to provide room for this movement when the clay soil expands and contracts; due to the variable water percentage present at any given time.